Clinical Study on Treatment of Chronic Persistent Bronchial Asthma
NCT ID: NCT03228134
Last Updated: 2023-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
320 participants
INTERVENTIONAL
2018-02-01
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study on the Prevention of Mild to Moderate Intermittent Asthma With Chinese Medicine Weiyang Yuping Fang
NCT04522726
Chinese Herbal Medicine Formula Combined With Inhaled Corticosteroids for the Treatment of Mild to Persistent Asthma in Children
NCT05066841
Multicenter Clinical Study on the Optimal Treatment Protocol and Outcome of Cough Variant Asthma With Chinese and Western Medicine
NCT05459805
Huang-long Zhi-xiao Granule Improves the Control Rate of Chronic Persistent of Asthma
NCT05841901
Experienced Chinese Herbal Formulas on Pediatric Asthma
NCT02341573
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study, investigators recruited chronic persistent asthma participants, and gave the corresponding western medicine background treatment and traditional Chinese medicine treatment program for 28 days.Participants will undergo a physical examination, lung function, blood and sputum collection.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hanxiao treatment group
80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
Ke Chuan Liu Wei Granule
Traditional Chinese Medicine
Hanxiao control group
80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule placebo oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
Ke Chuan Liu Wei Granule placebo
Placebo
Xuxiao treatment group
80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
Yang He Ping Chuan Granule
Traditional Chinese Medicine
Xuxiao control group
80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule placebo oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
Yang He Ping Chuan Granule placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ke Chuan Liu Wei Granule
Traditional Chinese Medicine
Yang He Ping Chuan Granule
Traditional Chinese Medicine
Ke Chuan Liu Wei Granule placebo
Placebo
Yang He Ping Chuan Granule placebo
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients had positive bronchodilator reversibility test or positive bronchial challenge test or more than 50 parts per billion of FENO before
* Conform to the predetermined 2 TCM Syndrome Types
* Patients who have given written informed consent
Exclusion Criteria
* With fever, or severity of intermittent state, high degree of sustained, or with respiratory failure, etc.
* Pulmonary emphysema, chronic obstructive pulmonary disease, pulmonary emphysema, pulmonary heart disease, pneumonia, lung cancer and other lung diseases
* Patients who are allergic to therapeutic medicine
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Longhua Hospital
OTHER
Shanghai University of Traditional Chinese Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fenglin Street Community Health Service Center
Shanghai, Shanghai Municipality, China
Kangjian Street Community Health Service Center
Shanghai, Shanghai Municipality, China
Tianping Street Community Health Service Center
Shanghai, Shanghai Municipality, China
Longhua Hospital Affiliated Shanghai University of TCM
Shanghai, Shanghai Municipality, China
Fengxian District Hospital of TCM
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017LCSY347
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.